SHARE PURCHASE AGREEMENTShare Purchase Agreement • October 6th, 1998 • Incyte Pharmaceuticals Inc • Services-commercial physical & biological research • California
5.5% Convertible Subordinated Notes Due 2007 INDENTUREIndenture • March 22nd, 2000 • Incyte Pharmaceuticals Inc • Services-commercial physical & biological research • New York
1 EXHIBIT 10.13 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the "Agreement") is made and entered into as of February 4, 2000, by and among Incyte Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Deutsche Bank...Registration Rights Agreement • March 22nd, 2000 • Incyte Pharmaceuticals Inc • Services-commercial physical & biological research • New York
andRights Agreement • September 30th, 1998 • Incyte Pharmaceuticals Inc • Services-commercial physical & biological research • Delaware
betweenSettlement Agreement • April 1st, 2002 • Incyte Genomics Inc • Services-commercial physical & biological research • California
Exhibit 1.1 ----------- JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G, dated October 4, 2001, (the "Schedule 13G"), with respect to the Common Stock, par value $0.001 per share, of Incyte Genomics Inc. is...Joint Filing Agreement • October 4th, 2001 • Incyte Genomics Inc • Services-commercial physical & biological research
The undersigned hereby agree that the Statement on this Schedule 13G, dated October 4, 2001, (the "Schedule 13G"), with respect to the Common Stock, par value $0.001 per share, of Incyte Genomics Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
EXHIBIT 10.23 EMPLOYMENT AGREEMENT -------------------- THIS EMPLOYMENT AGREEMENT (the "Agreement") by and between INCYTE GENOMICS, INC., a Delaware corporation (the "Company"), and ROY A. WHITFIELD (the "Executive"), dated as of the 2nd day of May,...Employment Agreement • August 14th, 2001 • Incyte Genomics Inc • Services-commercial physical & biological research • Delaware
INCYTE CORPORATION AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of November 14, 2013 0.375% Convertible Senior Notes due 2018Indenture • November 14th, 2013 • Incyte Corp • Services-commercial physical & biological research • New York
INDENTURE dated as of November 14, 2013 between INCYTE CORPORATION, a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01).
AMONGMerger Agreement • January 10th, 2001 • Incyte Genomics Inc • Services-commercial physical & biological research • Delaware
Exhibit 1.1 ----------- JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G/A, dated February 14, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, par value $0.001 per share, of Incyte Genomics...Joint Filing Agreement • February 14th, 2003 • Incyte Genomics Inc • Services-commercial physical & biological research
The undersigned hereby agree that the Statement on this Schedule 13G/A, dated February 14, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, par value $0.001 per share, of Incyte Genomics Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
EXHIBIT 99.1 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement") is made as of the 28th day of December, 2000 by and among Incyte Genomics, Inc., a Delaware corporation ("Incyte") and the stockholders of Proteome, Inc.,...Registration Rights Agreement • January 10th, 2001 • Incyte Genomics Inc • Services-commercial physical & biological research • Delaware
UNDERWRITING AGREEMENTUnderwriting Agreement • July 15th, 1997 • Incyte Pharmaceuticals Inc • Services-commercial physical & biological research • California
2. PURPOSE OF NOTE. Borrower acknowledges that it is a requirement of the loan evidenced by this Note (the "Loan") that the proceeds of the Loan be used ---- only to finance Borrower's principal residence located at the address set forth on Schedule 1...Promissory Note • August 14th, 2002 • Incyte Genomics Inc • Services-commercial physical & biological research
EXHIBIT 10.27 AMENDED AND RESTATED -------------------- EMPLOYMENT AGREEMENT -------------------- THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the "Agreement") by and between INCYTE GENOMICS, INC., a Delaware corporation (the "Company"), and James...Employment Agreement • April 1st, 2002 • Incyte Genomics Inc • Services-commercial physical & biological research • Delaware
Underwriting AgreementUnderwriting Agreement • September 25th, 2009 • Incyte Corp • Services-commercial physical & biological research • New York
Incyte Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 18,000,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 2,700,000 additional shares (the “Optional Securities”) of Common Stock, $.001 par value per share (“Stock”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
AMENDMENT TOEmployment Agreement • August 14th, 2002 • Incyte Genomics Inc • Services-commercial physical & biological research
AGREEMENT AND PLAN OF MERGERMerger Agreement • February 6th, 1998 • Incyte Pharmaceuticals Inc • Services-commercial physical & biological research • Delaware
EXHIBIT 10.28 AMENDED AND RESTATED -------------------- EMPLOYMENT AGREEMENT -------------------- THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the "Agreement") by and between INCYTE GENOMICS, INC., a Delaware corporation (the "Company"), and James...Employment Agreement • April 1st, 2002 • Incyte Genomics Inc • Services-commercial physical & biological research • Delaware
LEASELease • March 22nd, 2000 • Incyte Pharmaceuticals Inc • Services-commercial physical & biological research • California
AMENDMENT TOTransition Agreement • August 14th, 2002 • Incyte Genomics Inc • Services-commercial physical & biological research
Exhibit 10.41 July 25, 2002 Michael D. Lack PO Box 9876 Rancho Santa Fe, CA 92067 Dear Mike: This will confirm our agreement regarding your termination of employment with Incyte Genomics, Inc. (the "Company") on January 1, 2003 (the "Termination...Employment Agreement • August 14th, 2002 • Incyte Genomics Inc • Services-commercial physical & biological research
REGISTRATION RIGHTS AGREEMENT dated as of February 19, 2004 between INCYTE CORPORATION and MORGAN STANLEY & CO. INCORPORATED, as representative of the Initial PurchasersRegistration Rights Agreement • April 26th, 2004 • Incyte Corp • Services-commercial physical & biological research • New York
REGISTRATION RIGHTS AGREEMENT dated as of February 19, 2004 between Incyte Corporation, a Delaware corporation (the “Company”), and Morgan Stanley & Co. Incorporated, as representative of the several initial purchasers listed on Schedule I (the “Initial Purchasers”) to the Purchase Agreement dated February 12, 2004 (the “Purchase Agreement”) with the Company. In order to induce the Initial Purchasers to enter into the Purchase Agreement, the Company has agreed to provide the registration rights set forth in this Agreement. The execution of this Agreement is a condition to the closing under the Purchase Agreement.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 12th, 2016 • Incyte Corp • Services-commercial physical & biological research • New York
This Registration Rights Agreement (this “Agreement”) is made as of February 12, 2016, by and between Incyte Corporation, a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
Exhibit 10.40 FORM OF AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT TO EMPLOYMENT AGREEMENT (the "Amendment") by and between INCYTE GENOMICS, INC., a Delaware corporation (the "Company"), and _____________ (the "Executive"), is effective as of the...Employment Agreement • August 14th, 2002 • Incyte Genomics Inc • Services-commercial physical & biological research
THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement") is made as of the 23rd day of December, 1997 by and among INCYTE PHARMACEUTICALS, INC., a Delaware ---------------------------- corporation ("Incyte") and the stockholders of Synteni, Inc., a...Registration Rights Agreement • February 6th, 1998 • Incyte Pharmaceuticals Inc • Services-commercial physical & biological research • California
STOCK PURCHASE AGREEMENTStock Purchase Agreement • May 4th, 2017 • Incyte Corp • Services-commercial physical & biological research
This Stock Purchase Agreement (this “Agreement”) is dated as of February 14, 2017, between Agenus Inc., a Delaware corporation (the “Company”), and Incyte Corporation, a Delaware corporation (the “Purchaser”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 21st, 2013 • Incyte Corp • Services-commercial physical & biological research • Delaware
THIS EMPLOYMENT AGREEMENT (the “Agreement”) by and between INCYTE CORPORATION, a Delaware corporation (the “Company”), and (the “Executive”), effective as of the day of , 20 .
REGISTRATION RIGHTS AGREEMENT dated as of September 26, 2006 between INCYTE CORPORATION and PIPER JAFFRAY & CO.Registration Rights Agreement • September 28th, 2006 • Incyte Corp • Services-commercial physical & biological research • New York
REGISTRATION RIGHTS AGREEMENT dated as of September 26, 2006 between Incyte Corporation, a Delaware corporation (the “Company”), and Piper Jaffray & Co (the “Initial Purchaser”), who are parties to that certain Purchase Agreement dated September 20, 2006 (the “Purchase Agreement”). In order to induce the Initial Purchaser to enter into the Purchase Agreement, the Company has agreed to provide the registration rights set forth in this Agreement. The execution of this Agreement is a condition to the closing under the Purchase Agreement.
1 EXHIBIT 10.20 STOCK PURCHASE AGREEMENT Incyte Pharmaceuticals, Inc. 3174 Porter Drive Palo Alto, California 94304 The undersigned (the "Investor"), hereby confirms its agreement with you as follows: 1. This Stock Purchase Agreement (the "Agreement")...Stock Purchase Agreement • March 22nd, 2000 • Incyte Pharmaceuticals Inc • Services-commercial physical & biological research • California
SHARE SUBSCRIPTION AGREEMENT By and Between INCYTE CORPORATION and MERUS N.V. Dated as of December 20, 2016Share Subscription Agreement • June 30th, 2017 • Incyte Corp • Services-commercial physical & biological research • New York
THIS SHARE SUBSCRIPTION AGREEMENT (the “Agreement”) is made and entered into as of December 20, 2016 (the “Signing Date”), by and between Merus N.V., a public company with limited liability (naamloze vennootschap) incorporated under the laws of the Netherlands (the “Company”), and Incyte Corporation, a Delaware corporation (the “Purchaser”).
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 5th, 2020 • Incyte Corp • Services-commercial physical & biological research
Zur Vorlage beim Amtsgericht München – Handelsregister – bestätigen wir hiermit hinsichtlich der von dem Vorstand der Gesellschaft am [•] 2020 mit Zustimmung des Aufsichtsrats vom [•] 2020 beschlossenen Kapitalerhöhung über insgesamt € [•], dass wir heute der
Re: 0.375% Convertible Senior Notes due 2018 (CUSIP No. 45337CAK8) of Incyte Corporation (“2018 Notes”) and 1.25% Convertible Senior Notes due 2020 (CUSIP No. 45337CAL6) of Incyte Corporation (“2020 Notes”)Convertible Senior Notes Agreement • February 21st, 2017 • Incyte Corp • Services-commercial physical & biological research
By entering into this letter agreement (this “Agreement”), each party signing this Agreement under the heading “HOLDER” on the signature page hereto (each a “Holder” and, collectively, the “Holders”) and Incyte Corporation, a Delaware corporation (the “Company”) irrevocably agree as follows:
GLOBAL COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN MACROGENICS, INC. AND INCYTE CORPORATIONGlobal Collaboration and License Agreement • February 15th, 2018 • Incyte Corp • Services-commercial physical & biological research • New York
This GLOBAL COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is entered into as of October 24, 2017 (the “Execution Date”), by and between INCYTE CORPORATION, a Delaware corporation, having its principal place of business at 1801 Augustine Cut-Off, Wilmington, DE 19803 (hereinafter “Incyte”), and MACROGENICS, INC., a Delaware corporation, having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 (“MacroGenics”). Incyte and MacroGenics are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
HEXAGEN LIMITED SHARE EXCHANGE OPTION AGREEMENT ----------------------------------------Share Exchange Option Agreement • November 20th, 1998 • Incyte Pharmaceuticals Inc • Services-commercial physical & biological research
AMENDMENT NO. 4 TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • October 30th, 2019 • Incyte Corp • Services-commercial physical & biological research
THIS AMENDMENT NO. 4 TO COLLABORATION AND LICENSE AGREEMENT (this “Amendment No. 4”) is entered into as of the 5th day of April, 2016 (the “Effective Date”), by and between Incyte Corporation, a Delaware corporation having an office at 1801 Augustine Cut-Off, Wilmington, Delaware (“Incyte”), and Novartis International Pharmaceutical Ltd., a limited company organized under the laws of Bermuda having an office at 131 Front Street, Hamilton, Bermuda HM 12 (“Novartis”).
